Which patients with renal cancer may benefit from sunitinib therapy?

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 2, 2010, Pages 69-74

  Ferguson, Tom ^a   Gore, Martin ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; BIOLOGICAL MARKER; EVEROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ASTHENIA; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; EDITORIAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; THROMBOCYTOPENIA;

EID: 77955602985     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834009359411     Document Type: Editorial

References (31)

1. Bukowski, R.M., Eisen, T., Szczylik, C., Stadler, W.M., Simantov, R., Shan, M. et al. (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol ASCO Annual Meeting Proceedings Part I 25: 5023.
2. Choueiri, T.K., Vaziri, S.A., Rini, B.I., Elson, P., Bhalla, I., Jaeger, E. et al. (2007) Use of Von-Hippel Lindau (VHL) mutation status to predict objective response to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (RCC). J Clin Oncol ASCO Annual Meeting Proceedings 25: 5012.
3. Culine, S., Bekradda, M., Kramar, A., Rey, A., Escudier, B. and Droz, J.P. ( 1998) Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83: 2548-2553.
4. Deprimo, S.E. and Bello, C. ( 2007) Surrogate bio-markers in evaluating response to anti-angiogenic agents: focus on sunitinib. Ann Oncol 18(suppl 10): 11-19.
5. Drabkin, H.A., Figlin, R.A., Stadler, W.M., Hutson, T.E., Hajdenberg, J., Chu, L. et al. (2007) The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. J Clin Oncol ASCO Annual Meeting Proceedings Part I 25: 5041.
6. Duda, D.G., Batchelor, T.T., Willett, C.G. and Jain, R.K. ( 2007) VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 13: 223-230.
7. Dudek, A.Z., Zolnierek, J., Dham, A., Lindgren, B.R. and Szczylik, C. (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115: 61-67.
8. Escudier, B., Ravaud, A., Negrier, S., Szczylik, C., Bellmunt Molins, J., Bracarda, S. et al. (2008) Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J Clin Oncol ASCO Annual Meeting Proceedings 26: 5025.
9. Gore, M.E., Szczylik, C., Porta, C., Bracarda, S., Bjarnason, G.A., Oudard, S. et al. (2009) Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 10: 757-763.
10. Goss, G., Ferry, D., Wierzbicki, R., Laurie, S.A., Thompson, J., Biesma, B. et al. (2009) Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status. J Clin Oncol 27: 2253-2260.
11. Harbour, R. and Miller, J. ( 2001) A new system for grading recommendations in evidence based guidelines. BMJ 323: 334-336.
12. Helgason, H.H., Mallo, H.A., Droogendijk, H. and Haanen, J.G. ( 2008) Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol 26: 152-154.
13. Houk, B.E., Bello, C.L., Demetri, G.D., Michaelson, M., Casali, P., Bukowski, R. et al. (2008) Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches. American Association for Cancer Research Meeting Abstracts, Abstr 5828.
14. Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A. et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
15. Hutson, T., Davis, I.D., Macheils, J.H., de Souza, P.L., Baker, K., Bordogna, W. et al. (2008) Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol ASCO Annual Meeting Proceedings 26: 5046.
16. Klatte, T., Seligson, D.B., Riggs, S.B., Leppert, J.T., Berkman, M.K., Kleid, M.D. et al. (2007) Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 13: 7388-7393.
17. Medioni, J., Cojocarasu, O., Belcaceres, J.L., Halimi, P. and Oudard, S. ( 2007) Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 18: 1282-1283.
18. Motzer, R.J., Bacik, J., Murphy, B.A., Russo, P. and Mazumdar, M. ( 2002a) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296.
19. Motzer, R.J., Bacik, J., Mariani, T., Russo, P., Mazumdar, M. and Reuter, V. ( 2002b) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20: 2376-2381.
20. Motzer, R.J., Bacik, J., Schwartz, L.H., Reuter, V., Russo, P., Marion, S. et al. (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454-463.
21. Motzer, R.J., Rini, B.I., Bukowski, R.M., Curti, B.D., George, D.J., Hudes, G.R. et al. (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295: 2516-2524.
22. Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Rixe, O. et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124.
23. Motzer, R.J., Hutson, T.E., Tomczak, P., Michaelson, M.D., Bukowski, R.M., Oudard, S. et al. (2009) Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
24. Negrier, S. ( 2007) Sunitinib malate in patients with cerebellar metastases. Eur J Cancer Suppl 5: 32-34.
25. Patel, P.H., Chadalavada, R.S., Ishill, N.M., Patil, S., Reuter, V.E., Motzer, R.J. et al. (2008) Hypoxia-inducible factor (HIF) 1a and 2a levels in cell lines and human tumor predicts response to Sunitinib in renal cell carcinoma (RCC). J Clin Oncol ASCO Annual Meeting Proceedings 26: 5008.
26. Patyna, S. and Peng, J. ( 2006) Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer 4: 21.
27. Rini, B.I., Michaelson, M.D., Rosenberg, J.E., Bukowski, R.M., Sosman, J.A., Stadler, W.M. et al. (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26: 3743-3748.
28. Rosenberg, J.E., Motzer, R.J., Michaelson, M.D., Redman, B.G., Hudes, G.R., Bukowski R.M. et al. (2007) Sunitinib therapy for patients with metastatic renal cell carcinoma: updated results of two phase II trials and prognostic factor analysis for survival. J Clin Oncol ASCO Annual Meeting Proceedings 25: 5095.
29. Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J. et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98.
30. Tamaskar, I., Garcia, J.A., Elson, P., Wood, L., Mekhail, T., Dreicer, R. et al. (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179: 81-86.
31. Thomas, A.A., Rini, B.I., Lane, B.R., Garcia, J., Dreicer, R., Klein, E.A. et al. (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181: 518-523.